Secondary endpoints
bodyweight loss
SECONDARY
The relative and absolute reduction from baseline in bodyweight was greater with increasing survodutide dose, with bodyweight loss seen in all survodutide DGs in a dose-dependent manner (Fig. MMRM estimates for the relative change in bodyweight from baseline to EoT. Analysis of additional secondary endpoints showed that the proportion of participants with ≥5% and ≥10% reductions in bodyweight after 16 weeks’ treatment increased dose-dependently with survodutide (Table Proportion of participants achieving ≥5% and ≥10% bodyweight reductionsWaist circumference decreased from baseline with both survodutide and semaglutide treatment, but data were highly variable and associated with wide 95% CIs (ESM Fig. 